The search for improved systemic therapy of non-small cell lung cancer-What are today's options?

Lung Cancer

Volumn 72, Issue 3, 2011, Pages 265-270

  Fruh M ^a  

^a Rorschacherstrasse 95 ^*  (Switzerland)

Author keywords

Biomarkers; New systemic therapy; Non small cell lung cancer

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; NERATINIB; PACLITAXEL; PEMETREXED; PLACEBO; XL 184;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER SURVIVAL; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MUTATION; NAUSEA; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; GLUTAMATES; GUANINE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; QUINOLINES;

EID: 79955464912     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.02.020     Document Type: Review

References (62)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
3. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 2007, 448:561-566.
4. Subramanian J., Madadi A.R., Dandona M., Williams K., Morgensztern D., Govindan R., et al. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the clinicaltrials.gov website. J Thorac Oncol 2010, 5:1116-1119.
5. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625. NSCLC Meta-Analyses Collaborative Group.
6. Breathnach O.S., Freidlin B., Conley B., Green M.R., Johnson D.H., Gandara D.R., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2001, 19:1734-1742.
7. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
8. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3025-3034.
9. Douillard J.Y., Laporte S., Fossella F., Georgoulias V., Pujol J.L., Kubota K., et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol 2007, 2:939-946.
10. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47:69-80.
11. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. For the CISCA (CISplatin versus CArboplatin) Meta-analysis Group Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J Natl Cancer Inst 2007, 99:847-857.
12. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003, 95:362-372.
13. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999, 91:66-72. Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group.
14. Quoix E., Oster J.P., Westeel V., Pichon E., Zalcman G., Baudrin R.L., et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28:18s. [suppl; abstr 2].
15. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
16. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
17. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000, 18:2354-2362.
18. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
19. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
20. Johnson D.H., Fehrenbacher L., Novotny W.F., Herbst R.S., Nemunaitis J.J., Jablons D.M., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
21. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
22. Reck M., von Pawel J., Zatloukal P., Ramlau R., Gorbounova V., Hirsh V., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227-1234.
23. Sandler A., Yi J., Dahlberg S., Kolb M.M., Wang L., Hambleton J., et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol 2010, 51:416-423.
24. Shaked Y., Henke E., Roodhart J., Mancuso P., Langenberg M.H., Colleoni M., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
25. Dahlberg S.E., Sandler A.B., Brahmer J.R., Schiller J.H., Johnson D.H. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010, 28:949-954.
26. Goodwin R., Ding K., Seymour L., Lemaître A., Arnold A., Shepherd F.A., et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Ann Oncol 2010, 21:2220-2226.
27. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. FLEX Study Team Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open label randomised phase III trial. Lancet 2009, 373:1525-1531.
28. Lynch T.J., Patel T., Dreisbach L., McCleod M., Heim W.J., Hermann R.C., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010, 28:911-917.
29. Lin H., Jiang J., Liang X., Zhou X., Huang R. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer 2010, 70:57-62.
30. Socinski M.A., Schell M.J., Peterman A., Bakri K., Yates S., Gitten R., et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002, 20:1335-1343.
31. Park J.O., Kim S.W., Ahn J.S., Suh C., Lee J.S., Jang J.S., et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5233-5239.
32. Smith I.E., O'Brien M.E., Talbot D.C., Nicolson M.C., Mansi J.L., Hickish T.F., et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001, 19:1336-1343.
33. von Plessen C., Bergman B., Andresen O., Bremnes R.M., Sundstrom S., Gilleryd M., et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006, 95:966-973.
34. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
35. Cappuzzo F., Ciuleanu T., Stelmakh L., Cicenas S., Szczésna A., Juhász E., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
36. Fidias P.M., Dakhir S.R., Lyss A.P., Loesch D.M., Waterhouse D.M., Bromund J.L., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
37. Perol M., Chouaid C., Milleron B.J., Gervais R., Barlesi F., Westeel V., et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010, 28:15s. [suppl; abstr 7507].
38. Brodowicz T., Krzakowski M., Zwitter M., Tzekova V., Ramlau R., Ghilezan N., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163.
39. Belani C.P., Waterhouse D.M., Ghazal H., Ramalingam S.S., Bordoni R., Greenberg R., et al. Phase III study of maintenance gemcitabine and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin for patients with advanced non-small cell lung cancer. J Clin Oncol 2010, 28:15s. [suppl; abstr 7506].
40. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
41. Inoue A., Suzuki T., Fukuhara T., Maemondo M., Kimura Y., Morikawa N., et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006, 24:3340-3346.
42. Paz-Ares L., Sanchez J.M., García-Velasco A.B., Massuti G., López-Vivanco M., Provencio, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor. J Clin Oncol 2006, 24:18S. [suppl; abstr 7020].
43. Tamura K., Okamoto I., Kashii T., Negoro S., Hirashima T., Kudoh S., et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer 2008, 98:907-914.
44. Sutani A., Nagai Y., Udagawa K., Uchida Y., Koyama N., Murayama Y., et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp. Br J Cancer 2006, 95:1483-1489.
45. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
46. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonaryadenocarcinoma. N Engl J Med 2009, 361:947-957.
47. Yang C., Fukuoka M., Mok T.S., Wu Y.L., Thongprasert S., Saijo N., et al. Final overall survival results from a phase III, randomised, open-label, first-line study of gefitinib v carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). ESMO 2010, [abstract LBA2].
48. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
49. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
50. Zhou C., Wu Y.L., Chen G., Feng J., Liu X., Wang C., et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in Chinese advanced non-small-cell lung cancer patients with EGFR activating mutations. ESMO 2010, [abstr LBA13].
51. Lee J.S., Park K., Kim S.W., et al. A randomized study of Gefitinib (IRESSATM) versus standard chemotherapy (Gencitabine plus Cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. Thorac Oncol 2009, 4:4. [suppl: PRS].
52. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
53. Tapia C., Savic S., Bihl M., Rufle A., Zlobec I., Terracciano L., et al. EGFR mutation analysis in non-small-cell lung cancer: experience from routine diagnostics. Pathologe 2009, 30:384-392.
54. Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., Mikami I., et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27:1394-1400.
55. Minegishi Y., Maemondo M., Okinaga S., Morikawa N., Inoue A., Kobayashi K., et al. First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: multicenter phase II trial (NEJ 003 study). J Clin Oncol 2010, 28:15s. [suppl; abstr 7561].
56. Jackman D., Pao W., Riely G.J., Engelman J.A., Kris M.G., Jänne P.A., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
57. Oxnard G.R., Riely G.J., Arcila M.H., Kris M.G., Pao W., Ladanyi M., et al. Clinical course of patients with acquired resistance (to EGFR tyrosine kinase inhibitors. J Clin Oncol 2010, 28:15s. [suppl; abstr 7520].
58. Kosaka T., Yatabe Y., Endoh H., Yoshida K., Hida T., Tsuboi M., et al. Analysis of epidermal growth factor receptor gene mutation in patients with non small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769.
59. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
60. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.
61. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
62. Rosell R., Molina M.A., Costa C., Taron M., Bertran-Alamillo J., Mayo C., et al. Outcome to erlotinib in non-small cell lung cancer patients according to the presence of the EGFR T790M mutation and BRCA1 mRNA expression levels in pretreatment biopsies. J Clin Oncol 2010, 28:15s. [suppl; abstr 7514].